USPTO serial 88216665
RECON BIOINFORMATICS ENGINE
Reviewed by CopyMark Law Group
Reg. 5866191Status 710
- Filing date
- Status date
- Registration date
- Sep 24, 2019
- Examiner
- BENMAMAN, ALICE
- Law office
- TMO LAW OFFICE 116
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with RECON BIOINFORMATICS ENGINE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Cambridge, MA, US
Cambridge, MA, US
Cambridge, MA, US
Cambridge, MA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Monica Riva Talley
Monica Riva Talley STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C1100 NEW YORK AVENUE, N.W.WASHINGTON, DC 20005UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Conducting early evaluations in the field of new pharmaceuticals; consulting services in the fields of biotechnology and pharmaceutical research; pharmaceutical product development services; pharmaceutical product evaluation services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of pharmaceuticals for the treatment of cancer; research and development of vaccines and medicines; technical research in the field of pharmaceutical studies; development of platform technology, namely, cancer immunotherapy platforms for manufacturing therapeutics; conducting clinical trials for others in the field of pharmaceuticals for the treatment and prevention of cancer; and consulting services for others in the field of design, planning, and implementation of clinical trials | SECTION 8 - CANCELLED | Mar 2, 2018 |
| 044 | Medical and pharmaceutical consultation; providing information relating to therapeutic properties of pharmaceuticals | SECTION 8 - CANCELLED | Mar 2, 2018 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Neon Therapeutics, Inc.
- Other trademarks owned by Neon Therapeutics, Inc.
- Other trademarks owned by Neon Therapeutics, Inc.
- Other trademarks owned by BioNTech US Inc.
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named RECON BIOINFORMATICS ENGINE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 3, 2026 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Sep 24, 2024 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Jun 3, 2022 | C.7C | NEW CERTIFICATE UNDER SECTION 7 - PROCESSED | — |
| Jun 3, 2022 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jan 6, 2022 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| Sep 24, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 9, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 9, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 19, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 3, 2019 | ALIE | ASSIGNED TO LIE | — |
| May 18, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 17, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 16, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 16, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 5, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 5, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 5, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 4, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 22, 2018 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Dec 21, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 7, 2018 | NWAP | NEW APPLICATION ENTERED | — |